NCT07129239 - High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM) | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

August 20, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions

Wet Age-related Macular Degeneration (wAMD)

Interventions

OTHER

Maintenance

Patients who are currently being treated with EYLEA® (aflibercept 2mg) will be switched to EYLEA® HD (aflibercept 8mg) and maintain the current treatment interval that they had with EYLEA® (aflibercept 2mg), followed by an extension of therapy (or increase in treatment dosing interval) based on clinical response

Trial Locations (1)

H1Y0E2

Clinique de Retine de L'Est, Montreal